Claims for Patent: 5,980,864

Summary for Patent: 5,980,864

Title:	1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
Abstract:	1,4,7,10-Tetraazacyclodedecane butyltriols of general formula I.sub.A ##STR1## in which R.sup.1 means hydrogen or a metal ion equivalent independent of one another and R.sup.2 means a butyltriol radical as well as their salts with organic or inorganic bases or amino acids are valuable pharmaceutical agents.
Inventor(s):	Platzek; Johannes (Berlin, DE), Gries; Heinz (Berlin, DE), Weinmann; Hanns-Joachim (Berlin, DE), Schuhmann-Giampieri; Gabriele (Berlin, DE), Press; Wolf-Rudiger (Berlin, DE)
Assignee:	Schering Aktiengellsellschaft (Berlin, DE)
Application Number:	07/671,041
Patent Claims:	1. A 1,4,7,10-tetraazacyclododecane butyltriol of formula I.sub.A ##STR8## in which each R.sub.1 is hydrogen or a metal ion equivalent, independent of one another, and R.sub.2 is 1-hydroxymethyl-2,3-dihydroxypropyl, or a salt thereof with an organic or inorganic base or an amino acid. 2. A compound according to claim 1, wherein all R.sup.1 's are hydrogen atoms. 3. A compound according to claim 1, wherein at least two of substituents R.sup.1 are metal ion equivalents of at least one element of the atomic numbers 21-29, 42, 44 or 57-83 or at least one radionuclide of an element of the atomic numbers 27, 29, 31, 32, 37-39, 43, 49, 62, 64, 70 or 77. 4. 10-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4 ,7,10-tetraazacyclododecane, a compound of claim 1. 5. A compound of claim 1, wherein said metal ion equivalents are of at least one element of atomic numbers 21-29, 42, 44 or 58-70. 6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 7. A method of conducting NMR imaging comprising administering a composition of claim 6 effective therefor. 8. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier. 9. A method of conducting NMR imaging comprising administering a composition of claim 8. 10. The gadolinium (III) complex of 10-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10- tetraazacyclododecane. 11. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier. 12. A method of conducting NMR imaging comprising administering a composition of claim 11.